Global Colorectal Cancer Screening Market Size, Share & Industry Trends Analysis Report By Type (Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), By End-user, By Regional Outlook and Forecast,

Global Colorectal Cancer Screening Market Size, Share & Industry Trends Analysis Report By Type (Colonoscopy, Stool-based (Fecal Immunochemical Test (FIT), Fecal Occult Blood Test (FOBT), and Stool-DNA Test), By End-user, By Regional Outlook and Forecast, 2023 - 2030


The Global Colorectal Cancer Screening Market size is expected to reach $22.2 billion by 2030, rising at a market growth of 4.8% CAGR during the forecast period.

In United States, approximately nine out of ten people with colorectal cancer who are diagnosed early and treated appropriately are still alive five years later. Hence, the North America region would capture approximately 2/5th of the market by 2030. Due to several factors, including an aging population, an increase in cancer cases, high healthcare spending, and a modern healthcare infrastructure. The market is also expanding due to rising government initiatives to create awareness of the disease and the accessibility of screening tests like FIT and FOBT.

The major strategies followed by the market participants are Acquisitions as the key developmental strategy in order to keep pace with the changing demands of end users. For instance, In April, 2022, BioMerieux S.A. acquired Specific Diagnostics to enhances bioMérieux's capability to deliver instant AST results by adding specific Diagnostics' SPECIFIC REVEAL Rapid AST offerings to its portfolio. In December, 2022, Olympus Corporation took over Odin Vision to reinforce Olympus’ strategy for delivering digital patient care.

Based on the Analysis presented in the KBV Cardinal matrix; Siemens Healthineers AG is the forerunner in the Market. April, 2021, Siemens took over Varian Medical Systems to strengthen the competitiveness & independence of Siemens Healthineers. Companies such as Fujifilm Holdings Corporation, Olympus Corporation, BioMerieux S.A. are some of the key innovators in the Market.

COVID-19 Impact Analysis

The COVID-19 effect caused the market growth to slow down during the pandemic. Pandemic-era lockdown limitations and a suspension of colorectal cancer screening brought this on. To decrease person-to-person contact and conserve hospital and medical resources for those exposed to COVID-19, screening through colonoscopies was completely discontinued in many countries in 2020. The market slowed in growth during the pandemic period when measured by revenue. During the pandemic, there was a decrease in the number of people being examined through government programs.

Market Growth Factors

Growing Risk of Colorectal Cancer

The substantial rise in global colorectal cancer incidence is one of the key factors that favorably influence the market's expansion. The incidence is highest in developed nations, rising in middle- and low-income nations because of unhealthy lifestyle choices and an aging population explosion. Additionally, according to the American Cancer Society, 43,340 new instances of rectal cancer and 104,610 new cases of colon cancer were identified in the United States in 2020, respectively. The demand for CRC detection has increased due to the rising incidence of CRC and the disease's rising death rate, which will likely drive the expansion of the market in the following years.

Government Cancer Screening Policies

Governments in several nations have strengthened screening policies to reduce the incidence of colorectal cancer on a global scale. Governments in several nations have implemented various initiatives, such as regular screening programs for individuals at risk of contracting the disease, to reduce the growing burden of CRC. In Korea, the National Cancer Screening Program offers CRC screening to all adults over 50 at no or at a low cost, according to a study released by the National Library of Medicine in 2019. The usage of various tests is anticipated to increase due to the growing elderly population and government initiatives, which will fuel market expansion overall.

Market Restraining Factors

Negative Effects of Colonoscopies May Lead to Decreased Adoption of Testing

Despite the critical and growing need for advanced and efficient screening procedures, adopting screening devices may be hampered by their inherent limitations. A colonoscopy, for instance, has the highest incidence of positive results and is a highly accurate test. However, the patient may experience several negative side effects from the colonoscopy process, including bleeding and infection. During the forecast period, these restrictions and unfavorable effects related to colorectal cancer screening techniques are anticipated to restrain market expansion.

Type Outlook

By type, the market is segmented into stool-based, colonoscopy, and others. The stool-based segment covered a considerable revenue share in the market in 2022. The diagnosis of colorectal cancer and precancerous lesions using stool-based tests has shown encouraging results, making it a useful tool for early detection. The revolutionary stool-based tests analyze stool samples to find specific DNA markers related to colorectal cancer. Increased government programs for colorectal cancer screening and the efficiency of stool-based tests have contributed to the segment's growth.

Stool-based type Outlook

Under the stool-based segment, the market is further divided into fecal immunochemical test (FIT), fecal occult blood test (FOBT), and stool-DNA test. The fecal immunochemical test (FIT) segment witnessed the largest revenue share in the market in 2022. The FIT, or fecal immunochemical test, is a non-invasive diagnostic procedure used to identify blood in stool. FITs are extensively utilized diagnostic tools for detecting precancerous lesions or early-stage colorectal cancer by detecting blood in stool samples. The development of FITs has focused on enhancing their sensitivity, specificity, and patient friendliness.

End-user Outlook

Based on end-user, the market is bifurcated into hospital & clinics, clinical laboratories, diagnostic imaging centers, and others. In 2022, the hospitals and clinics segment dominated the market with maximum revenue share. The growth of the segment is attributable to the rise in the prevalence of colorectal cancer and technological advancements in screening tests conducted in hospitals globally. The demand for CRC screening is expanding in hospitals and clinics due to elements including a sizable number of hospitals.

Regional Outlook

Region-wise, the market is analysed across North America, Europe, Asia Pacific, and LAMEA. In 2022, the Asia Pacific region acquired a significant revenue share in the market. The expansion of the regional market is driven by the development and upgrading of healthcare facilities in Asian nations, rising CRC incidence in the region's nations, and rising individual consciousness of better treatment outcomes. It is expected that the rising incidence of colorectal cancer in the region's key countries and the status of colorectal diseases as the primary cause of mortality will also drive market growth in the region.

The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Novigenix SA, Eiken Chemical Co., Ltd., Clinical Genomics Pathology, Inc., Exact Sciences Corporation, Epigenomics AG, BioMerieux S.A., Olympus Corporation, Sysmex Corporation, Fujifilm Holdings Corporation, and Siemens Healthineers AG (Siemens AG)

Strategies deployed in Colorectal Cancer Screening Market

Jul-2023: BioMerieux S.A. signed a partnership with Oxford Nanopore, a medical technology company, to provide nanopore sequencing solutions within the infectious disease diagnostics market. The partnership provides BioMerieux with opportunities for exploring new technologies for improved patient care.

Dec-2022: Olympus Corporation took over Odin Vision, an endoscopy solutions provider. The acquisition reinforces Olympus’ strategy for delivering digital patient care.

Apr-2022: BioMerieux S.A. acquired Specific Diagnostics, an antimicrobial susceptibility test (AST) specialist. The acquisition enhances bioMérieux's capability to deliver instant AST results by adding specific Diagnostics' SPECIFIC REVEAL Rapid AST offerings to its portfolio.

May-2021: Fujifilm Holdings Corporation signed a partnership with Helio Health, an AI-powered healthcare solutions provider, to develop solutions for early detection of liver cancer. The partnership would provide clinicians around the world with market-leading diagnostic and surveillance technologies.

Apr-2021: Siemens took over Varian Medical Systems, a U.S. company active in the region of cancer research & therapy. This acquisition would allow Siemens to strengthen the competitiveness & independence of Siemens Healthineers. The acquisition further focused on creating a world-leading company in cancer therapy.

Jan-2021: Fujifilm Holdings Corporation expanded its geographical footprint by opening a new centre named “NURA” in Bangalore, India. The centre would serve as a medical screening service business for the company.

Scope of the Study

Market Segments covered in the Report:

By Type
  • Colonoscopy
  • Stool-based
  • Fecal Immunochemical Test (FIT)
  • Fecal Occult Blood Test (FOBT)
  • Stool-DNA Test
  • Others
By End-user
  • Hospitals & Clinics
  • Clinical Laboratories
  • Diagnostic Imaging Centres
  • Others
By Geography
  • North America
  • US
  • Canada
  • Mexico
  • Rest of North America
  • Europe
  • Germany
  • UK
  • France
  • Russia
  • Spain
  • Italy
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • India
  • South Korea
  • Singapore
  • Malaysia
  • Rest of Asia Pacific
  • LAMEA
  • Brazil
  • Argentina
  • UAE
  • Saudi Arabia
  • South Africa
  • Nigeria
  • Rest of LAMEA
Companies Profiled
  • Novigenix SA
  • Eiken Chemical Co., Ltd.
  • Clinical Genomics Pathology, Inc.
  • Exact Sciences Corporation
  • Epigenomics AG
  • BioMerieux S.A.
  • Olympus Corporation
  • Sysmex Corporation
  • Fujifilm Holdings Corporation
  • Siemens Healthineers AG (Siemens AG)
Unique Offerings from KBV Research
  • Exhaustive coverage
  • Highest number of market tables and figures
  • Subscription based model available
  • Guaranteed best price
  • Assured post sales research support with 10% customization free


Chapter 1. Market Scope & Methodology
1.1 Market Definition
1.2 Objectives
1.3 Market Scope
1.4 Segmentation
1.4.1 Global Colorectal Cancer Screening Market, by Type
1.4.2 Global Colorectal Cancer Screening Market, by End-user
1.4.3 Global Colorectal Cancer Screening Market, by Geography
1.5 Methodology for the research
Chapter 2. Market at a Glance
2.1 Key Highlights
Chapter 3. Market Overview
3.1 Introduction
3.1.1 Overview
3.1.1.1 Market Composition and Scenario
3.2 Key Factors Impacting the Market
3.2.1 Market Drivers
3.2.2 Market Restraints
Chapter 4. Competition Analysis - Global
4.1 KBV Cardinal Matrix
4.2 Recent Industry Wide Strategic Developments
4.2.1 Partnerships, Collaborations and Agreements
4.2.2 Product Launches and Product Expansions
4.2.3 Acquisition and Mergers
4.2.4 Geographical Expansions
4.3 Top Winning Strategies
4.3.1 Key Leading Strategies: Percentage Distribution (2019-2023)
4.3.2 Key Strategic Move: (Mergers & Acquisition: 2019, Jul – 2022, Dec) Leading Players
4.4 Porter’s Five Forces Analysis
Chapter 5. Global Colorectal Cancer Screening Market by Type
5.1 Global Colonoscopy Market by Region
5.2 Global Stool-based Market by Region
5.3 Global Colorectal Cancer Screening Market by Stool-based Type
5.3.1 Global Fecal Immunochemical Test (FIT) Market by Region
5.3.2 Global Fecal Occult Blood Test (FOBT) Market by Region
5.3.3 Global Stool-DNA Test Market by Region
5.4 Global Others Market by Region
Chapter 6. Global Colorectal Cancer Screening Market by End-user
6.1 Global Hospitals & Clinics Market by Region
6.2 Global Clinical Laboratories Market by Region
6.3 Global Diagnostic Imaging Centres Market by Region
6.4 Global Others Market by Region
Chapter 7. Global Colorectal Cancer Screening Market by Region
7.1 North America Colorectal Cancer Screening Market
7.1.1 North America Colorectal Cancer Screening Market by Type
7.1.1.1 North America Colonoscopy Market by Country
7.1.1.2 North America Stool-based Market by Country
7.1.1.3 North America Colorectal Cancer Screening Market by Stool-based Type
7.1.1.3.1 North America Fecal Immunochemical Test (FIT) Market by Country
7.1.1.3.2 North America Fecal Occult Blood Test (FOBT) Market by Country
7.1.1.3.3 North America Stool-DNA Test Market by Country
7.1.1.4 North America Others Market by Country
7.1.2 North America Colorectal Cancer Screening Market by End-user
7.1.2.1 North America Hospitals & Clinics Market by Country
7.1.2.2 North America Clinical Laboratories Market by Country
7.1.2.3 North America Diagnostic Imaging Centres Market by Country
7.1.2.4 North America Others Market by Country
7.1.3 North America Colorectal Cancer Screening Market by Country
7.1.3.1 US Colorectal Cancer Screening Market
7.1.3.1.1 US Colorectal Cancer Screening Market by Type
7.1.3.1.2 US Colorectal Cancer Screening Market by End-user
7.1.3.2 Canada Colorectal Cancer Screening Market
7.1.3.2.1 Canada Colorectal Cancer Screening Market by Type
7.1.3.2.2 Canada Colorectal Cancer Screening Market by End-user
7.1.3.3 Mexico Colorectal Cancer Screening Market
7.1.3.3.1 Mexico Colorectal Cancer Screening Market by Type
7.1.3.3.2 Mexico Colorectal Cancer Screening Market by End-user
7.1.3.4 Rest of North America Colorectal Cancer Screening Market
7.1.3.4.1 Rest of North America Colorectal Cancer Screening Market by Type
7.1.3.4.2 Rest of North America Colorectal Cancer Screening Market by End-user
7.2 Europe Colorectal Cancer Screening Market
7.2.1 Europe Colorectal Cancer Screening Market by Type
7.2.1.1 Europe Colonoscopy Market by Country
7.2.1.2 Europe Stool-based Market by Country
7.2.1.3 Europe Colorectal Cancer Screening Market by Stool-based Type
7.2.1.3.1 Europe Fecal Immunochemical Test (FIT) Market by Country
7.2.1.3.2 Europe Fecal Occult Blood Test (FOBT) Market by Country
7.2.1.3.3 Europe Stool-DNA Test Market by Country
7.2.1.4 Europe Others Market by Country
7.2.2 Europe Colorectal Cancer Screening Market by End-user
7.2.2.1 Europe Hospitals & Clinics Market by Country
7.2.2.2 Europe Clinical Laboratories Market by Country
7.2.2.3 Europe Diagnostic Imaging Centres Market by Country
7.2.2.4 Europe Others Market by Country
7.2.3 Europe Colorectal Cancer Screening Market by Country
7.2.3.1 Germany Colorectal Cancer Screening Market
7.2.3.1.1 Germany Colorectal Cancer Screening Market by Type
7.2.3.1.2 Germany Colorectal Cancer Screening Market by End-user
7.2.3.2 UK Colorectal Cancer Screening Market
7.2.3.2.1 UK Colorectal Cancer Screening Market by Type
7.2.3.2.2 UK Colorectal Cancer Screening Market by End-user
7.2.3.3 France Colorectal Cancer Screening Market
7.2.3.3.1 France Colorectal Cancer Screening Market by Type
7.2.3.3.2 France Colorectal Cancer Screening Market by End-user
7.2.3.4 Russia Colorectal Cancer Screening Market
7.2.3.4.1 Russia Colorectal Cancer Screening Market by Type
7.2.3.4.2 Russia Colorectal Cancer Screening Market by End-user
7.2.3.5 Spain Colorectal Cancer Screening Market
7.2.3.5.1 Spain Colorectal Cancer Screening Market by Type
7.2.3.5.2 Spain Colorectal Cancer Screening Market by End-user
7.2.3.6 Italy Colorectal Cancer Screening Market
7.2.3.6.1 Italy Colorectal Cancer Screening Market by Type
7.2.3.6.2 Italy Colorectal Cancer Screening Market by End-user
7.2.3.7 Rest of Europe Colorectal Cancer Screening Market
7.2.3.7.1 Rest of Europe Colorectal Cancer Screening Market by Type
7.2.3.7.2 Rest of Europe Colorectal Cancer Screening Market by End-user
7.3 Asia Pacific Colorectal Cancer Screening Market
7.3.1 Asia Pacific Colorectal Cancer Screening Market by Type
7.3.1.1 Asia Pacific Colonoscopy Market by Country
7.3.1.2 Asia Pacific Stool-based Market by Country
7.3.1.3 Asia Pacific Colorectal Cancer Screening Market by Stool-based Type
7.3.1.3.1 Asia Pacific Fecal Immunochemical Test (FIT) Market by Country
7.3.1.3.2 Asia Pacific Fecal Occult Blood Test (FOBT) Market by Country
7.3.1.3.3 Asia Pacific Stool-DNA Test Market by Country
7.3.1.4 Asia Pacific Others Market by Country
7.3.2 Asia Pacific Colorectal Cancer Screening Market by End-user
7.3.2.1 Asia Pacific Hospitals & Clinics Market by Country
7.3.2.2 Asia Pacific Clinical Laboratories Market by Country
7.3.2.3 Asia Pacific Diagnostic Imaging Centres Market by Country
7.3.2.4 Asia Pacific Others Market by Country
7.3.3 Asia Pacific Colorectal Cancer Screening Market by Country
7.3.3.1 China Colorectal Cancer Screening Market
7.3.3.1.1 China Colorectal Cancer Screening Market by Type
7.3.3.1.2 China Colorectal Cancer Screening Market by End-user
7.3.3.2 Japan Colorectal Cancer Screening Market
7.3.3.2.1 Japan Colorectal Cancer Screening Market by Type
7.3.3.2.2 Japan Colorectal Cancer Screening Market by End-user
7.3.3.3 India Colorectal Cancer Screening Market
7.3.3.3.1 India Colorectal Cancer Screening Market by Type
7.3.3.3.2 India Colorectal Cancer Screening Market by End-user
7.3.3.4 South Korea Colorectal Cancer Screening Market
7.3.3.4.1 South Korea Colorectal Cancer Screening Market by Type
7.3.3.4.2 South Korea Colorectal Cancer Screening Market by End-user
7.3.3.5 Singapore Colorectal Cancer Screening Market
7.3.3.5.1 Singapore Colorectal Cancer Screening Market by Type
7.3.3.5.2 Singapore Colorectal Cancer Screening Market by End-user
7.3.3.6 Malaysia Colorectal Cancer Screening Market
7.3.3.6.1 Malaysia Colorectal Cancer Screening Market by Type
7.3.3.6.2 Malaysia Colorectal Cancer Screening Market by End-user
7.3.3.7 Rest of Asia Pacific Colorectal Cancer Screening Market
7.3.3.7.1 Rest of Asia Pacific Colorectal Cancer Screening Market by Type
7.3.3.7.2 Rest of Asia Pacific Colorectal Cancer Screening Market by End-user
7.4 LAMEA Colorectal Cancer Screening Market
7.4.1 LAMEA Colorectal Cancer Screening Market by Type
7.4.1.1 LAMEA Colonoscopy Market by Country
7.4.1.2 LAMEA Stool-based Market by Country
7.4.1.3 LAMEA Colorectal Cancer Screening Market by Stool-based Type
7.4.1.3.1 LAMEA Fecal Immunochemical Test (FIT) Market by Country
7.4.1.3.2 LAMEA Fecal Occult Blood Test (FOBT) Market by Country
7.4.1.3.3 LAMEA Stool-DNA Test Market by Country
7.4.1.4 LAMEA Others Market by Country
7.4.2 LAMEA Colorectal Cancer Screening Market by End-user
7.4.2.1 LAMEA Hospitals & Clinics Market by Country
7.4.2.2 LAMEA Clinical Laboratories Market by Country
7.4.2.3 LAMEA Diagnostic Imaging Centres Market by Country
7.4.2.4 LAMEA Others Market by Country
7.4.3 LAMEA Colorectal Cancer Screening Market by Country
7.4.3.1 Brazil Colorectal Cancer Screening Market
7.4.3.1.1 Brazil Colorectal Cancer Screening Market by Type
7.4.3.1.2 Brazil Colorectal Cancer Screening Market by End-user
7.4.3.2 Argentina Colorectal Cancer Screening Market
7.4.3.2.1 Argentina Colorectal Cancer Screening Market by Type
7.4.3.2.2 Argentina Colorectal Cancer Screening Market by End-user
7.4.3.3 UAE Colorectal Cancer Screening Market
7.4.3.3.1 UAE Colorectal Cancer Screening Market by Type
7.4.3.3.2 UAE Colorectal Cancer Screening Market by End-user
7.4.3.4 Saudi Arabia Colorectal Cancer Screening Market
7.4.3.4.1 Saudi Arabia Colorectal Cancer Screening Market by Type
7.4.3.4.2 Saudi Arabia Colorectal Cancer Screening Market by End-user
7.4.3.5 South Africa Colorectal Cancer Screening Market
7.4.3.5.1 South Africa Colorectal Cancer Screening Market by Type
7.4.3.5.2 South Africa Colorectal Cancer Screening Market by End-user
7.4.3.6 Nigeria Colorectal Cancer Screening Market
7.4.3.6.1 Nigeria Colorectal Cancer Screening Market by Type
7.4.3.6.2 Nigeria Colorectal Cancer Screening Market by End-user
7.4.3.7 Rest of LAMEA Colorectal Cancer Screening Market
7.4.3.7.1 Rest of LAMEA Colorectal Cancer Screening Market by Type
7.4.3.7.2 Rest of LAMEA Colorectal Cancer Screening Market by End-user
Chapter 8. Company Profiles
8.1 Novigenix SA
8.1.1 Company Overview
8.1.2 SWOT Analysis
8.2 Eiken Chemical Co., Ltd.
8.2.1 Company Overview
8.2.2 Financial Analysis
8.2.3 Research & Development Expenses
8.3 Clinical Genomics Pathology, Inc.
8.3.1 Company Overview
8.3.2 Recent strategies and developments:
8.3.2.1 Partnerships, Collaborations, and Agreements:
8.3.3 SWOT Analysis
8.4 Exact Sciences Corporation
8.4.1 Company Overview
8.4.2 Financial Analysis
8.4.3 Regional Analysis
8.4.4 Research & Development Expenses
8.4.5 Recent strategies and developments:
8.4.5.1 Acquisition and Mergers:
8.4.6 SWOT Analysis
8.5 Epigenomics AG
8.5.1 Company Overview
8.5.2 Financial Analysis
8.5.3 Regional Analysis
8.5.4 Research & Development Expenses
8.5.5 SWOT Analysis
8.6 BioMerieux S.A.
8.6.1 Company Overview
8.6.2 Financial Analysis
8.6.3 Segmental and Regional Analysis
8.6.4 Research & Development Expenses
8.6.5 Recent strategies and developments:
8.6.5.1 Partnerships, Collaborations, and Agreements:
8.6.5.2 Acquisition and Mergers:
8.6.6 SWOT Analysis
8.7 Olympus Corporation
8.7.1 Company Overview
8.7.2 Financial Analysis
8.7.3 Segmental and Regional Analysis
8.7.4 Research & Development Expenses
8.7.5 Recent strategies and developments:
8.7.5.1 Partnerships, Collaborations, and Agreements:
8.7.5.2 Product Launches and Product Expansions:
8.7.5.3 Acquisition and Mergers:
8.7.6 SWOT Analysis
8.8 Sysmex Corporation
8.8.1 Company Overview
8.8.2 Financial Analysis
8.8.3 Regional Analysis
8.8.4 Research & Development Expense
8.8.5 SWOT Analysis
8.9 Siemens Healthineers AG (Siemens AG)
8.9.1 Company Overview
8.9.2 Financial Analysis
8.9.3 Segmental and Regional Analysis
8.9.4 Research & Development Expense
8.9.4.1 Acquisition and Mergers:
8.9.5 SWOT Analysis
8.10. Fujifilm Holdings Corporation
8.10.1 Company Overview
8.10.2 Financial Analysis
8.10.3 Segmental and Regional Analysis
8.10.4 Research & Development Expenses
8.10.5 Recent strategies and developments:
8.10.5.1 Partnerships, Collaborations, and Agreements:
8.10.5.2 Product Launches and Product Expansions:
8.10.5.3 Geographical Expansions:
8.10.6 SWOT Analysis
Chapter 9. Winning Imperative for Colorectal Cancer Screening Market

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings